Triferic maintained hemoglobin near the baseline level, while pla

Triferic maintained hemoglobin near the baseline level, while placebo resulted in a statistically significant decline from baseline. The LS mean treatment difference was 3.6 g/L from baseline to end of treatment (p < 0.001). The Triferic treatment effect was significant in all pre-defined subgroups. Triferic, via dialysate, provided sustained delivery of iron for erythropoiesis while maintaining reticulocyte

hemoglobin (CHr). Serum ferritin did not increase in the Triferic group during the study despite iron administration with each treatment. The tolerability, types and incidence of adverse and serious adverse events with Triferic were similar to placebo. With Triferic, no anaphylaxis occurred with 20,000 individual doses and no increase in intradialytic hypotension, cardiovascular events, infections, or vascular access thrombotic events relative to placebo were AZD6244 manufacturer observed. No death was attributed to Triferic. Conclusion: In CKD-HD patients, the novel iron salt Triferic, infused via hemodialysate for up to 48 weeks, is well tolerated with a safety profile similar to placebo. Triferic is effective in maintaining hemoglobin without increasing body iron stores as indicated by stable ferritin levels. WU PING-HSUN1,4, LIN MING-YEN1,6, WANG ANGELA YEE-MOON7, LIN YI-TING2,3, KUO MEI-CHUAN1,5,

CHIU YI-WEN1,5, HWANG SHANG-JYH1,5, CHEN HUNG-CHUN1,5 1Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Forskolin manufacturer Hospital, Kaohsiung, Taiwan; 2Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; 3Department of Public Health, Kaohsiung Medical University,

Kaohsiung, Taiwan; 4Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; 5Faculty of Renal Care, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; 6Technology Research Center, National Applied Research Laboratories, Taiwan; 7Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong Introduction: End stage renal disease is associated with a high risk of coronary artery disease, which is one of the leading causes of death among dialysis patients. However, there is so far no randomized study Ergoloid comparing the effectiveness of aspirin versus thienopyridines for secondary prevention of acute coronary syndrome in dialysis patients. This study aimed to compare the efficacy of aspirin versus thienopyridines in reducing the subsequent risk of recurrent acute coronary syndrome and mortality in a national cohort of Taiwan dialysis patients who was hospitalized with acute coronary syndrome. Methods: We conducted a nationwide follow-up study, based on the Taiwan National Health Insurance Research Database. We identified incident dialysis patients who were experienced with an episode of acute coronary syndrome between during 1998 and 2006 were identified.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>